In the fast-evolving medical device industry, maintaining regulatory compliance during mergers and acquisitions is crucial. Companies need to navigate complex regulatory landscapes to avoid post-transaction complications that could disrupt market access and operations.
Emergo by UL’s Regulatory Due Diligence service is designed to assess the current state of regulatory compliance of the medical devices involved, identifying discrepancies and gaps to minimize post-transaction risks.
ANSWERED ON THIS PAGE:
- What is the objective of the Regulatory Due Diligence service?
- What does the Regulatory Due Diligence service include?
- When is the Regulatory Due Diligence service appropriate?
Emergo’s service offerings
Emergo’s Regulatory Due Diligence service includes evaluating the state of compliance of medical devices affected by a planned merger or acquisition in order to identify any issues to be addressed before completion of the transaction. This process helps minimize the risk of post-transaction regulatory and compliance complications.
Our Regulatory Due Diligence service includes a comprehensive review of the target company’s regulatory documentation and quality management system (QMS). We assess the company’s technical documentation, including key elements such as risk management and post-market surveillance processes. In addition, we evaluate the manufacturer’s key regulatory obligations. We also review the roles and responsibilities of economic operators and key sections of the manufacturer’s vigilance system.
When is Emergo’s Regulatory Due Diligence service needed?
The Regulatory Due Diligence service is relevant for any company involved in mergers and acquisitions within the medical device industry, especially those planning to invest in, acquire or merge with another entity. It is crucial for companies looking to verify the compliance status of their target to avoid post-transaction issues. This service is, therefore, relevant when preparing for a merger or acquisition, providing essential insights before finalizing the transaction. The service is particularly beneficial for companies expanding into new markets, acquiring new product lines or integrating complex regulatory frameworks in order to support a smooth transition and continued market access.
Common questions about Emergo’s Regulatory Due Diligence service
Why is the Regulatory Due Diligence service important for medical device companies during M&A?
Regulatory Due Diligence helps companies understand the current compliance status of their targets, helping to identify and address any regulatory issues before completing the transaction. By identifying compliance gaps early, companies can proactively manage and mitigate regulatory risks, thereby protecting their investment and maintaining business continuity.
What are the key benefits of using Emergo’s Regulatory Due Diligence service?
Emergo provides in-depth assessments for regulatory compliance and QMS status, offering clear insights and actionable recommendations to address any gaps. Our regulatory experience and expertise support companies in meeting regulatory requirements, reducing the risk of delays and penalties. In addition, our end-to-end service offerings help streamline the overall M&A process, enabling a more efficient and effective transition.
How does Emergo maintain the quality and accuracy of the Regulatory Analysis service?
With over 25 years of experience and a global presence in over 20 markets, Emergo’s team of experts leverages deep regulatory knowledge to deliver accurate and actionable insights tailored to your specific M&A needs.
X
Request more information from our specialists
Thanks for your interest in our products and services. Let's collect some information so we can connect you with the right person.
Please wait…